Handheld nebulizer manufacturer HCmed Innovations announced that it has accepted an invitation to build an R&D center and production facility in the newly opened Wuxi International Life Science Innovation Park, which is anchored by AstraZeneca. HCMed’s Deepro smart vibrating mesh nebulizers can be used for delivery of AstraZeneca’s Pulmicort Respules, the company pointed out.
AstraZeneca China VP Tina Xu commented, “AstraZeneca is full with experience in multiple diseases treatments and we look forward to working with the municipal government and Wuxi High-tech District to create a influential ecosystem that can support and accelerate the development of startup company from early research and development through to commercialization, which would benefit patients in China and global.”
In January 2018, HCmed announced that Vivo Capital’s PANDA Fund had made a strategic investment in the company and later that year said that it had received approval for the device in Indonesia and had partnered with Pharos to launch the nebulizer there. According to the most recent announcement, the Deepro device has also received approvals in Europe, Taiwan, and Brazil, with a Brazilian launch taking place in May 2019.
Read the HCmed Innovations press release.
